circulating tumor DNA
Guardant Health Q3 Revenues Up 27 Percent
The company's recorded record revenue for the quarter of $92.6 million, driven by increases in its precision oncology clinical testing business.
Natera Builds Data Backing Serial ctDNA Changes to Aid CRC Patient Management, Treatment Decisions
Premium
The company believes its findings are the first to show that quantifying ctDNA changes can stratify high-risk colorectal cancer patients into better and worse prognostic groups.
Personal Genome Diagnostics, Cleveland Clinic Join Forces to Advance Liquid Biopsy
Leaders from collaborating Cleveland Clinic institutes will work with PGDx to optimize its ctDNA test reporting and adapt its technology for new oncology applications.
Molecular Health, Eone-Diagnomics Genome Center Ink Liquid Biopsy Partnership
EDGC will use Molecular Health's genomics interpretation software to provide circulating tumor DNA sequencing test results for cancer precision medicine.
Delfi Diagnostics Tags Lung Cancer as First Target for Fragmentation-Based Liquid Biopsy Tech
Premium
Based on promising early results, the company is now conducting a larger case-control study to lock in a classifier for prospective validation in an intended-use population.